Management EfficiencyThe company has return on total asset (ROA) of (39.47) % which means that it has lost $39.47 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (79.11) % meaning that it created substantial loss on money invested by shareholders.
Entity SummaryCatabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts. Catabasis Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 36 people.Catabasis Pharmaceuticals (CATB) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 36 people. Catabasis Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Catabasis Pharmaceuticals Leadership Team
Stock Performance Indicators